Chiral molecules in hypertension: Focus on S-amlodipine

Journal of Association of Physicians of India

Volumn 52, Issue MAR, 2004, Pages 187-188

  Adik Pathak, Lekha ^a,b  

^a Nanavati Heart Institute   (India)

^b GRANT MEDICAL COLLEGE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; CALCIUM CHANNEL BLOCKING AGENT;

BLOOD PRESSURE; DRUG EFFECT; EDITORIAL; HUMAN; HYPERTENSION; STEREOISOMERISM;

AMLODIPINE; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; HUMANS; HYPERTENSION; STEREOISOMERISM;

EID: 8744287889     PISSN: 00045772     EISSN: 00045772     Source Type: Journal    
DOI: None     Document Type: Editorial

References (6)

1. Webster J, Robb OJ, Jeffers TA, Scott AK, Pibrie JC, Towler HM. Once daily amlodipine in the treatment of mild to moderate hypertension. Br J Clin Pharmacol 1987;24:713-9.
2. Pharmacotherapy of Hypotension. Ch. 26 Satoskar RS et al in Pharmacology and Pharmacotherapeuties, Popular Prakashan. 386-417.
3. Lorfen H, Litold M. Enontio slictior disposition of oral amlodipine in healthy volunteers. Chirality 1994;6:531-6.
4. Hirmoth MS, Dighe G. A randomized, double-blind, double dummy, multicentric, horollel group. Comparative clinical trial of S-amlodipine 2.5 mg were amlodipine 5 mg in the treatment of mild to moderate hypertension. JAMA - India 2002;1:86-92.
5. Zhang XP, Loke KE, Mital S, Chohwala S, Hintze TH. Paradoxical release of nitric oxide by an L-left calcium channel antagonist, the R+ in antiomir of amlodipine. J Cardiovas Pharmacol 2002;39:208-14.
6. Pathak Lekha, Hiremath MS, Kerkar PG, Manade VG. Multicentric, clinical trial of S-amlodipine 2.5 mg versus amlodipine 5 mg in the treatment of mild to moderate hypertension - A randomised double blind clinical trial. JAPI 2004;52: 197-202.